Method of improved diuresis in individuals with impaired renal function

Abstract

Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

1 . A pharmaceutical composition comprising between about 15 mg to about 100 mg of KW-3902 and a non-adenosine modifying diuretic.  
     
     
         2 . The composition of  claim 1 , wherein the diuretic is a proximal diuretic.  
     
     
         3 . The composition of  claim 1 , wherein the diuretic is a loop diuretic.  
     
     
         4 . The composition of  claim 1 , wherein the diuretic is a distal diuretic.  
     
     
         5 . The composition of  claim 1 , wherein the diuretic is selected from the group consisting of hydrochlorothiazides, furosemide, torsemide, bumetanide, ethacrynic acid, piretanide, spironolactone, triamterene, and amiloridethiazides.  
     
     
         6 . The composition of  claim 1 , wherein the pharmaceutical composition contains about 15 mg of KW-3902.  
     
     
         7 . The composition of  claim 1 , wherein the pharmaceutical composition contains about 30 mg of KW-3902.  
     
     
         8 . The composition of  claim 1 , wherein the pharmaceutical composition contains about 60 mg of KW-3902.  
     
     
         9 . The composition of  claim 1 , wherein the pharmaceutical composition contains about 100 mg of KW-3902.  
     
     
         10 . The composition of  claim 1 , wherein the diuretic is furosemide.  
     
     
         11 . The composition of  claim 10 , comprising between about 20 mg to about 160 mg of furosemide.  
     
     
         12 . The composition of  claim 11 , wherein the pharmaceutical composition contains about 20 mg of furosemide.  
     
     
         13 . The composition of  claim 11 , wherein the pharmaceutical composition contains about 40 mg of furosemide.  
     
     
         14 . The composition of  claim 11 , wherein the pharmaceutical composition contains about 80 mg of furosemide.  
     
     
         15 . The composition of  claim 10 , wherein furosemide is administered through continuous infusion.  
     
     
         16 . The composition of  claim 15 , wherein furosemide is administered at a rate of between about 1 mg per hour to about 160 mg per hour.  
     
     
         17 . The composition of  claim 1 , further comprising a pharmaceutically acceptable diluent, excipient, or carrier.  
     
     
         18 . The composition of  claim 1 , wherein said composition is suitable for intravenous administration to a human.  
     
     
         19 . A pharmaceutical composition comprising about 30 mg of KW-3902 and about 40 mg of furosemide.  
     
     
         20 . A pharmaceutical composition suitable for intravenous administration to a human comprising about 30 mg of KW-3902 and about 40 mg of furosemide.